Literature DB >> 2309517

Exacerbation of myasthenia gravis by norfloxacin.

E H Rauser, R E Ariano, B A Anderson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2309517     DOI： 10.1177/106002809002400219

Source DB:  PubMed          Journal:  DICP        ISSN： 1042-9611


× No keyword cloud information.
  6 in total

1.  Case report: prescribing caution. When a simple disease isn't so simple.

Authors:  Cremona Ticea; James M Wright
Journal:  Can Fam Physician       Date:  2003-02       Impact factor: 3.275

Review 2.  Tolerability of fluoroquinolone antibiotics. Past, present and future.

Authors:  P Ball; G Tillotson
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

3.  Probable exacerbation of myasthenia gravis by ofloxacin.

Authors:  E Azevedo; J A Ribeiro; J Polónia; C Pontes
Journal:  J Neurol       Date:  1993-09       Impact factor: 4.849

Review 4.  Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.

Authors:  S Christopher Jones; Alfred Sorbello; Robert M Boucher
Journal:  Drug Saf       Date:  2011-10-01       Impact factor: 5.606

Review 5.  Quinolones: review of psychiatric and neurological adverse reactions.

Authors:  Ana M Tomé; Augusto Filipe
Journal:  Drug Saf       Date:  2011-06-01       Impact factor: 5.606

Review 6.  Clinical features and management of adverse effects of quinolone antibacterials.

Authors:  J H Paton; D S Reeves
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.